Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:7/31/2014)... July 31, 2014 Endo International plc (NASDAQ: ... quarter 2014 revenues of $719 million, an increase of ... $712 million. Endo reported net income of $21 million ... of $35 million in the second quarter of 2013.  ... net income for the three months ended June 30, 2014 ...
(Date:7/31/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced that the Company will receive a ... Asahi Kasei Pharma Corporation (Asahi Kasei). The payment ... a regulatory application to the Japanese Pharmaceutical and ... (collagenase clostridium histolyticum) for the treatment of Dupuytren,s ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- Recovery time ... cholesterol-lowering medications known as statins, according to a new ... drugs may affect the body,s inflammatory response, reducing the ... And that seemed to be particularly true among people ... become one of the most widely prescribed medications in ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
(Date:7/31/2014)... a unique protein that has the unusual property of destroying ... therefore be continually recreated and is no stable protein. The ... of coagulated blood. If you get a blood clot, it ... accumulated in a blood vessel, and therefore PAI-1 is extremely ... for helping people with a blood clot or other blood ...
(Date:7/31/2014)... 2014 Healthinsurancefacts.org has released a ... insurance plans by comparing quotes. , In order ... should consider comparing quotes. They can do this by ... simple questionnaire. , Clients should do proper research ... health insurance policies, and each of them can be ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... will host its first-ever event in New York on ... Eventi Hotel in Manhattan. , Featuring keynotes by ... Assemblyman Steve Katz (R-Yorktown), the event will include lunch ... Compassionate Care Act and the work NCIA is doing ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Breakthrough in understanding of important blood protein 2Health News:Breakthrough in understanding of important blood protein 3Health News:Comparing Health Insurance Quotes Can Help Clients Find Affordable Plans 2Health News:THURSDAY, AUG 7: First-Ever National Cannabis Industry Association Event in New York Will Feature Senator Savino, Assemblyman Katz, & Industry Leaders 2
... however , MONDAY, Nov. 9 (HealthDay News) -- After a ... of cancer recurrence in the affected breast, a new study ... increased risk of developing breast cancer, and experts have suspected ... increased risk of cancer recurrence at the site of the ...
... Nov. 9 Abt Associates continues to ... consulting and support services with three recently awarded contracts ... Agency,s (FEMA) Office of Regional Operations, the National Commission ... Transit Authority (WMATA). The value of the combined ...
... WASHINGTON, Nov. 9 The American Academy of Physician ... assistants (PAs) practicing in the United States, applauds the ... care reform bill, H.R. 3962, the Affordable Health Care ... this reform bill will ultimately lower the cost of ...
... release is available in French . Montreal, November 9, ... female. In human bodies trillions of cells are coupled, too, and ... these don,t come in twos, they are regrouped into indistinguishable clusters. ... and illness scientists have long searched for ways to splice ...
... the world suffer from cataracts. Thomas Kohnen of the ... surgery with the implantation of an artificial lens in ... ( Dtsch Arztebl Int 2009; 106[43]: 695�). ... In Germany alone, more than 600,000 cataract operations are ...
... reason why African Americans are not receiving kidney/pancreas transplants ... racial groups. Dr. Keith Melancon, director of kidney ... professor of surgery at Georgetown University Medical Center, and ... the American Journal of Transplantation . ...
Cached Medicine News:Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2
... True/Flex technology which has revolutionized the treatment ... unique fluted titanium construct was used in ... The biology of the tibia, with its ... presents special challenges to the healing process. ...
... 3080/3085 SP Bariatric Foot Extension provides extraordinary ... surgical capabilities for Amsco 3080 and 3085 ... Extension is rated for patients up to ... and easy attachment and full positioning capability. ...
... care you can provide to your patients, ... including innovative products, standardization and reimbursement guidelines, ... lavage systems deliver the performance needed for ... and foreign material. Each provides controlled pressure ...
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
Medicine Products: